Waldenström macroglobulinemia (WM) is a low-grade lymphoproliferative disorder characterized by the presence of an immunoglobulin M monoclonal protein in the blood and monoclonal small lymphocytes and lymphoplasmacytoid cells in the marrow. The disease is uncommon and there is a lack of clear diagnostic criteria. WM is treatable but not curable and long-term survival is possible. Therefore, the treating physician needs to carefully balance the risks and benefits of treatment. Treatments are aimed at relieving symptoms resulting from marrow infiltration and the hyperviscosity syndrome. Therapies available for initiation of treatment include alkylating agents, purine nucleoside analogs, and rituximab. Chlorambucil has been the mainstay of treatment for many years and remains useful, especially in older patients. Rituximab has become an important new therapy for this disease because of its positive treatment responses, acceptable toxicity, and lack of therapyassociated myelosuppression and myelodysplasia. Currently, rituximab is being combined with chemotherapy. Other options of treatment include interferon and corticosteroids. Emerging therapies include stem cell transplantation (autologous and allogeneic) for younger patients. Currently, there are few comparative data on which to state an absolute opinion concerning the best available treatment for patients with WM.
KeywordsChronic Lymphocytic Leukemia Fludarabine Overall Response Rate Main Drug Interaction Chlorambucil
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 5.Garcia-Sanz, R., Montoto S, Torrequebrada A, et al.: Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001, 115:575–582. This is a report of 217 patients presenting with WM in Spain over 10 years. It presents the clinical features, the prognostic factors, the treatments received, and the causes of death of these patients.PubMedCrossRefGoogle Scholar
- 7.Pangalis G, Angelopoulou M, Vassilakopoulos P: Bchronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström’s macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 1999, 36:104–114.PubMedGoogle Scholar
- 9.Kyle RA, Therneau TM, Rajkumar SV, et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002, 346:564–569. Monoclonal gammopathy of undetermined significance progressed in 115 of 1384 patients to MM, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma. This is the largest follow-up study of patients with MGUS.PubMedCrossRefGoogle Scholar
- 10.Gertz MA, Kyle RA: Hyperviscosity syndrome. J Intensive Care 1995, 10:128–141.Google Scholar
- 11.Kyle RA, Greipp PR, Gertz MA, et al.: Waldenström’s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000, 108:737–742. Seventy-nine percent of 24 patients administered continuous therapy had an objective improvement by reduction of serum M protein or increase in hemoglobin. Sixty-eight percent of 22 patients administered chlorambucil intermittently had an objective response. This is one of the most important studies showing effectiveness of chlorambucil in patients with WM.PubMedCrossRefGoogle Scholar
- 14.Dhodapkar MV, Jacobson JL, Gertz MA, et al.: Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001, 98:41–48. One hundred eighty-two patients with symptomatic or progressive disease were treated with four to eight cycles of therapy with fludarabine. The overall rate of response to therapy was 36%, with 2% complete remission. Patients who were 70 years or older had a substantially lower likelihood of response.PubMedCrossRefGoogle Scholar
- 18.Dimopoulos MA, Zervas C, Zomas A, et al.: Treatment of Waldenström’s macroglobulinemia with rituximab. J Clin Oncol 2002, 20:2327–2333. This is a prospective phase II study to define the activity of rituximab in patients with WM. Responses occurred in 40% of previously untreated patients and 50% of pretreated patients.PubMedCrossRefGoogle Scholar
- 20.Witzig TE, Gordon LI, Cabanillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002, 20:2453–2463.PubMedCrossRefGoogle Scholar
- 21.Kapff C, Jandl J: Blood: Atlas and Sourcebook of Hematology. Boston: Little Brown; 1991.Google Scholar
- 31.Dimopoulos MA, Zomas A, Viniou NA, et al.: Treatment of Waldenström’s macroglobulinemia with thalidomide. J Clin Oncol 2001, 19:3595–3601.Google Scholar